Fresh analysis indicates that individuals who stop using new slimming jabs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Research printed in a prominent medical journal shows that while overweight individuals can lose substantial amounts of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"People using such drugs should be aware of the potential of quick weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
Such speed of regain means a reversion to original mass in about a year and a half.
Comparing Treatments
The research, which reviewed dozens of trials involving over 9,000 of participants, contrasted the results of the injectable medications with older methods.
Researchers point out that people who lose weight through dieting usually see a slower weight regain—around 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Doctors suggest the mechanism of the injections is key to understanding the accelerated weight return.
These medications copy a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal might result in the system to produce less of its own natural hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating a significant risk."
A Lifelong Issue?
Medical guidelines suggest the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts contend that, considering the high risk of relapse, the treatment should be considered long-term.
This view is supported by pharmaceutical companies, who say that the findings "highlight the long-term nature of excess weight," similar to managing diseases like diabetes.
Patient Experiences
Users who have come off the jabs report a sudden return of hunger.
"It was like a trigger flipping and you become ravenous," said one woman.
This challenge is exacerbated if patients have not adopted sustainable lifestyle or habit changes during therapy.
Growing Use
Survey data show that millions of people in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is higher among females compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are powerful agents for weight loss, they are not a magic fix and lasting health benefits hinges on ongoing lifestyle changes.
